Business
aTyr is a clinical-stage biopharma company built around tRNA synthetase biology, with efzofitimod and additional immunology and fibrosis candidates.
aTyr revenue fell and losses widened, while cash burn improved and one insider buyer added $911.8K of purchases.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical immunology and fibrosis pipelineNote
- Revenue — Revenue fell 19.1%Watch
- Losses — Net loss widened to $74.1MWatch
- Cash — FCF improved to -$62.1MOK
- Balance sheet — Equity fell 3.6%Watch
- Insiders — 2 buys / 3 sells; $911.8K boughtOK
- Accounting — Altman-Z distress; other screens unavailableWatch
Where the revenue comes from
Fiscal 2025, as aTYR PHARMA INC reports it. History and quarterly detail are in the app.
- Collaboration Revenue$200K
Leadership changes
From aTYR PHARMA INC's own filings, the day they're filed.
- Eric Benevich · director · appointmenteff. 2024-12-10
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-06-08
- 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about aTYR PHARMA INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.